rewire.itbenchmarks
Method

Morgan + MLP

Baseline implemented by the Therapeutics Data Commons authors over the stated molecular featurisation.

22 evaluations · 22 results

Overview

Baseline implemented by the Therapeutics Data Commons authors over the stated molecular featurisation.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Evaluations and results

22 evaluations · 22 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-AMES: Toxicity: TDC.AMES
Dataset subset: TDC.AMES (TDC ADMET benchmark group split)
0.794 ± 0.008 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.008

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-AMES: Toxicity: TDC.AMES

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Toxicity), row(Morgan + MLP), column(TDC.AMES)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-AQSOL: Absorption: TDC.AqSol
Dataset subset: TDC.AqSol (TDC ADMET benchmark group split)
1.203 ± 0.019 mae
error · lower

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.019

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-AQSOL: Absorption: TDC.AqSol

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.AqSol)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-BBB: Distribution: TDC.BBB
Dataset subset: TDC.BBB (TDC ADMET benchmark group split)
0.823 ± 0.015 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.015

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-BBB: Distribution: TDC.BBB

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Distribution), row(Morgan + MLP), column(TDC.BBB)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-BIOAV: Absorption: TDC.Bioav
Dataset subset: TDC.Bioav (TDC ADMET benchmark group split)
0.581 ± 0.086 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.086

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-BIOAV: Absorption: TDC.Bioav

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.Bioav)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CACO2: Absorption: TDC.Caco2
Dataset subset: TDC.Caco2 (TDC ADMET benchmark group split)
0.908 ± 0.060 mae
error · lower

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.060

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CACO2: Absorption: TDC.Caco2

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.Caco2)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CL-HEPA: Excretion: TDC.CL-Hepa
Dataset subset: TDC.CL-Hepa (TDC ADMET benchmark group split)
0.272 ± 0.068 spearman
correlation · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.068

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CL-HEPA: Excretion: TDC.CL-Hepa

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Excretion), row(Morgan + MLP), column(TDC.CL-Hepa)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CL-MICRO: Excretion: TDC.CL-Micro
Dataset subset: TDC.CL-Micro (TDC ADMET benchmark group split)
0.492 ± 0.020 spearman
correlation · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.020

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CL-MICRO: Excretion: TDC.CL-Micro

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Excretion), row(Morgan + MLP), column(TDC.CL-Micro)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP2C9-INHIBITION: Metabolism: TDC.CYP2C9 Inhibition
Dataset subset: TDC.CYP2C9 Inhibition (TDC ADMET benchmark group split)
0.715 ± 0.004 auprc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.004

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP2C9-INHIBITION: Metabolism: TDC.CYP2C9 Inhibition

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP2C9 Inhibition)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP2C9-SUBSTRATE: Metabolism: TDC.CYP2C9 Substrate
Dataset subset: TDC.CYP2C9 Substrate (TDC ADMET benchmark group split)
0.380 ± 0.015 auprc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.015

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP2C9-SUBSTRATE: Metabolism: TDC.CYP2C9 Substrate

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP2C9 Substrate)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP2D6-INHIBITION: Metabolism: TDC.CYP2D6 Inhibition
Dataset subset: TDC.CYP2D6 Inhibition (TDC ADMET benchmark group split)
0.587 ± 0.011 auprc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.011

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP2D6-INHIBITION: Metabolism: TDC.CYP2D6 Inhibition

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP2D6 Inhibition)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP2D6-SUBSTRATE: Metabolism: TDC.CYP2D6 Substrate
Dataset subset: TDC.CYP2D6 Substrate (TDC ADMET benchmark group split)
0.671 ± 0.066 auprc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.066

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP2D6-SUBSTRATE: Metabolism: TDC.CYP2D6 Substrate

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP2D6 Substrate)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP3A4-INHIBITION: Metabolism: TDC.CYP3A4 Inhibition
Dataset subset: TDC.CYP3A4 Inhibition (TDC ADMET benchmark group split)
0.827 ± 0.009 auprc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.009

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP3A4-INHIBITION: Metabolism: TDC.CYP3A4 Inhibition

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP3A4 Inhibition)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-CYP3A4-SUBSTRATE: Metabolism: TDC.CYP3A4 Substrate
Dataset subset: TDC.CYP3A4 Substrate (TDC ADMET benchmark group split)
0.633 ± 0.013 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.013

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-CYP3A4-SUBSTRATE: Metabolism: TDC.CYP3A4 Substrate

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Metabolism), row(Morgan + MLP), column(TDC.CYP3A4 Substrate)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-DILI: Toxicity: TDC.DILI
Dataset subset: TDC.DILI (TDC ADMET benchmark group split)
0.832 ± 0.021 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.021

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-DILI: Toxicity: TDC.DILI

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Toxicity), row(Morgan + MLP), column(TDC.DILI)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-HALF-LIFE: Excretion: TDC.Half Life
Dataset subset: TDC.Half Life (TDC ADMET benchmark group split)
0.329 ± 0.083 spearman
correlation · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.083

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-HALF-LIFE: Excretion: TDC.Half Life

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Excretion), row(Morgan + MLP), column(TDC.Half_Life)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-HERG: Toxicity: TDC.hERG
Dataset subset: TDC.hERG (TDC ADMET benchmark group split)
0.736 ± 0.023 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.023

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-HERG: Toxicity: TDC.hERG

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Toxicity), row(Morgan + MLP), column(TDC.hERG)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-HIA: Absorption: TDC.HIA
Dataset subset: TDC.HIA (TDC ADMET benchmark group split)
0.807 ± 0.072 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.072

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-HIA: Absorption: TDC.HIA

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.HIA)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-LD50: Toxicity: TDC.LD50
Dataset subset: TDC.LD50 (TDC ADMET benchmark group split)
0.649 ± 0.019 mae
error · lower

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.019

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-LD50: Toxicity: TDC.LD50

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Toxicity), row(Morgan + MLP), column(TDC.LD50)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-LIPO: Absorption: TDC.Lipo
Dataset subset: TDC.Lipo (TDC ADMET benchmark group split)
0.701 ± 0.009 mae
error · lower

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.009

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-LIPO: Absorption: TDC.Lipo

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.Lipo)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-PGP: Absorption: TDC.Pgp
Dataset subset: TDC.Pgp (TDC ADMET benchmark group split)
0.880 ± 0.006 auroc
fraction · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.006

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-PGP: Absorption: TDC.Pgp

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Absorption), row(Morgan + MLP), column(TDC.Pgp)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-PPBR: Distribution: TDC.PPBR
Dataset subset: TDC.PPBR (TDC ADMET benchmark group split)
12.848 ± 0.362 mae
error · lower

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.362

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-PPBR: Distribution: TDC.PPBR

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Distribution), row(Morgan + MLP), column(TDC.PPBR)
Method: Morgan + MLPTask: TDC ADMET benchmark group TDC-VD: Distribution: TDC.VDss
Dataset subset: TDC.VDss (TDC ADMET benchmark group split)
0.493 ± 0.011 spearman
correlation · higher

Uncertainty: type: reported_plus_minus_type_unresolved; value: 0.011

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Morgan + MLP on TDC ADMET benchmark group TDC-VD: Distribution: TDC.VDss

Scaffold split, as the ADMET benchmark group defines it. Table 4 reports a value and a plus-or-minus spread but does not identify the spread's statistical meaning.

Aggregation: Not reported

Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development · Table 4, block(Distribution), row(Morgan + MLP), column(TDC.VD)

Source checking is not independent reproduction. Release 2026-09-29-06401fd5b220.

Use this model

How it works, versions and access
Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-09-29-06401fd5b220
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

View linked audit checks and correction history

Release 2026-09-29-06401fd5b220 · Record review: source checked

1 source records and release historyDownload this release
Technical metadata and extraction receipts

Stable ID: tdc-method-morgan-plus-mlp

areas
molecular-interactions
source locator
Table 4, row(Morgan + MLP)
missing metadata
checkpoint revision: unreported; parameters: unextracted
Related records

Suggest a correction